Thursday, June 11, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

Metastatic Lung Cancer

Register Today for This CNE (NCPD) Virtual Event — 1.5 Credit Hours Available

Live Webinar

Join Us on Thursday, June 11
5:00 PM – 6:30 PM ET

Complimentary Registration
A link to the event will be provided after registration.


Kelly EH Goodwin, MSN, RN, ANP-BC
Thoracic Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

Wendi S Lee, MSN, RN, NP-C
Department of Thoracic/Head and Neck
Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Suresh S Ramalingam, MD
Professor of Hematology and Medical Oncology
Roberto C Goizueta Chair for Cancer Research
Director, Division of Medical Oncology
Deputy Director, Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York


Neil Love, MD
Research To Practice
Miami, Florida

Topics for Discussion

  • Module 1: Long-Term Management of EGFR-Positive Disease
  • Module 2: Current Treatment Algorithms for Patients with ALK- or ROS1-Positive Disease
  • Module 3: Management of RET-Positive Non-Small Cell Lung Cancer (NSCLC) and Other Potentially Targetable Mutations
  • MODULE 4: Clinical Approach to Metastatic NSCLC without a Targetable Mutation
  • MODULE 5: Small Cell Lung Cancer — Current and Future Management
A detailed agenda will be made available in the coming weeks.

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Develop an understanding of the biologic basis for the investigation of immune checkpoint inhibitors for patients with advanced non-small cell (NSCLC) and small cell lung cancer (SCLC).
  • Evaluate recently published clinical trial data with the use of an anti-PD-1/PD-L1 antibody in combination with etoposide/platinum chemotherapy as first-line treatment of patients with extensive-stage SCLC, and identify individuals appropriate for treatment with this novel approach.
  • Recognize the incidence of genetic abnormalities commonly identified in patients with NSCLC, and counsel patients regarding how these may predict potential response (or lack thereof) to targeted therapy.
  • Review recent therapeutic advances related to the long-term management of metastatic NSCLC and an EGFR tumor mutation, and discern how this information should be applied to current patient care outside of a research setting.
  • Recall available clinical trial data documenting the safety and efficacy of approved ALK inhibitors in order to communicate to patients with ALK-rearranged metastatic NSCLC the rationale for individualized treatment recommendations.
  • Assess other oncogenic pathways (eg, ROS1, MET, RET, etc) mediating the growth of tumors in unique subsets, and recall published data with commercially available and experimental agents exploiting these targets.
  • Appreciate available clinical trial data with and the current role of anti-PD-1/PD-L1 antibodies alone or in combination with chemotherapy ± anti-angiogenic agents as first-line therapy for patients with metastatic NSCLC.
  • Consider existing guideline recommendations and expert perspectives regarding the selection and sequencing of available therapeutic options for patients with NSCLC who progress following first-line treatment with an immune checkpoint inhibitor.
  • Educate patients about the side effects associated with therapies commonly employed in the management of lung cancer, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with NSCLC and SCLC to optimize clinical and quality-of-life outcomes.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.